Progress of research on trifluridine-tipiracil usage in gastrointestinal malignancies
10.12007/j.issn.0258-4646.2023.12.013
- VernacularTitle:曲氟尿苷替匹嘧啶在消化道肿瘤中的研究进展
- Author:
Jiayun ZOU
1
;
Shuling ZHANG
;
Ying WANG
Author Information
1. 中国医科大学附属盛京医院肿瘤科,沈阳 110004
- Keywords:
trifluridine-tipiracil;
gastrointestinal malignancies;
combination therapy;
colorectal cancer
- From:
Journal of China Medical University
2023;52(12):1131-1134,1149
- CountryChina
- Language:Chinese
-
Abstract:
Trifluridine-tipiracil(TAS-102)is an oral chemotherapeutic agent combination comprising a fluoropyrimidine(FTD)and a potent thymidine phosphorylase(TPI)inhibitor.TAS-102 is novel due to its antitumor activity against 5-fluorouracil resistant tumors,demonstrated both by in vitro models and xenografts.TAS-102 is currently approved as a third-line therapeutic strategy for metastatic colorectal and gastric cancer based on phase Ⅲrandomized clinical trial data confirming survival benefits with TAS-102.Preliminary data from recent studies suggest a potential expanding role of TAS-102 in various gastrointestinal(GI)cancers.This article summarizes the clinical applications of TAS-102 in the treatment of GI cancers.Additionally,we discuss the rationale and clinical benefits of combining TAS-102 with other anticancer agents in patients with GI cancers.
